Half-Life Fundamentals
A peptide's half-life determines how long it remains active in the system and directly influences optimal dosing frequency. Understanding this relationship is crucial for effective research protocols.
Short Half-Life Peptides
GHRP-6 (15-60 minutes) requires multiple daily doses to maintain effects. Its rapid clearance means researchers typically dose 2-3 times daily for sustained activity.
DSIP (15-25 minutes) has an extremely short half-life, often requiring precise timing for sleep research applications.
Gonadorelin (2-4 minutes) requires pulsatile dosing to mimic natural GnRH release patterns.
Long Half-Life Peptides
CJC-1295 with DAC (6-8 days) allows once or twice weekly dosing due to its extended release profile created by the Drug Affinity Complex.
Steady-State Considerations
It takes approximately 5 half-lives to reach steady-state concentrations. For research planning, this means:
- Short half-life peptides reach steady-state quickly
- Long half-life peptides may take weeks to achieve consistent levels
Practical Applications
Match dosing frequency to half-life: short half-life peptides need frequent dosing, while long half-life peptides risk accumulation with too-frequent administration.
Research Protocol Design
Consider half-life when designing washout periods between different peptides or when switching protocols.
This information is for research purposes only and not medical advice.